Seroatlas · Human Serome Atlas

PLA2G6

85/88 kDa calcium-independent phospholipase A2

Also known as: iPLA2, iPLA2beta, NBIA2, PARK14, PLPL9_HUMAN, PNPLA9

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
O60733
Gene
PLA2G6
Ensembl
ENSG00000184381
Chromosome
22
Canonical length
806 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins
Subcellular location
Nuclear speckles,Plasma membrane,Microtubules
Quaternary structure
Homodimer

OverviewNCBI Gene

The protein encoded by this gene is an A2 phospholipase, a class of enzyme that catalyzes the release of fatty acids from phospholipids. The encoded protein may play a role in phospholipid remodelling, arachidonic acid release, leukotriene and prostaglandin synthesis, fas-mediated apoptosis, and transmembrane ion flux in glucose-stimulated B-cells. Several transcript variants encoding multiple isoforms have been described, but the full-length nature of only three of them have been determined to date. [provided by RefSeq, Dec 2010]

Canonical amino-acid sequenceUniProt

806 residues, UniProt reviewed canonical sequence.

>O60733|PLA2G6
     1  MQFFGRLVNT FSGVTNLFSN PFRVKEVAVA DYTSSDRVRE EGQLILFQNT PNRTWDCVLV
    61  NPRNSQSGFR LFQLELEADA LVNFHQYSSQ LLPFYESSPQ VLHTEVLQHL TDLIRNHPSW
   121  SVAHLAVELG IRECFHHSRI ISCANCAENE EGCTPLHLAC RKGDGEILVE LVQYCHTQMD
   181  VTDYKGETVF HYAVQGDNSQ VLQLLGRNAV AGLNQVNNQG LTPLHLACQL GKQEMVRVLL
   241  LCNARCNIMG PNGYPIHSAM KFSQKGCAEM IISMDSSQIH SKDPRYGASP LHWAKNAEMA
   301  RMLLKRGCNV NSTSSAGNTA LHVAVMRNRF DCAIVLLTHG ANADARGEHG NTPLHLAMSK
   361  DNVEMIKALI VFGAEVDTPN DFGETPTFLA SKIGRLVTRK AILTLLRTVG AEYCFPPIHG
   421  VPAEQGSAAP HHPFSLERAQ PPPISLNNLE LQDLMHISRA RKPAFILGSM RDEKRTHDHL
   481  LCLDGGGVKG LIIIQLLIAI EKASGVATKD LFDWVAGTST GGILALAILH SKSMAYMRGM
   541  YFRMKDEVFR GSRPYESGPL EEFLKREFGE HTKMTDVRKP KVMLTGTLSD RQPAELHLFR
   601  NYDAPETVRE PRFNQNVNLR PPAQPSDQLV WRAARSSGAA PTYFRPNGRF LDGGLLANNP
   661  TLDAMTEIHE YNQDLIRKGQ ANKVKKLSIV VSLGTGRSPQ VPVTCVDVFR PSNPWELAKT
   721  VFGAKELGKM VVDCCTDPDG RAVDRARAWC EMVGIQYFRL NPQLGTDIML DEVSDTVLVN
   781  ALWETEVYIY EHREEFQKLI QLLLSP

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PLA2G6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
2
Mean surface accessibility (rSASA)
0.27
Highest tissue expression
47 nTPM

Expression across tissuesHPA

Tissue

  • thyroid gland: 47 nTPM
  • testis: 40 nTPM
  • prostate: 23 nTPM
  • ovary: 22 nTPM
  • kidney: 22 nTPM
  • fallopian tube: 22 nTPM

Single-cell type

  • epicardial cells: 628 nCPM
  • megakaryocyte-erythroid progenitors: 251 nCPM
  • enterocytes: 176 nCPM
  • endometrial glandular cells: 162 nCPM
  • ovarian stromal cells: 124 nCPM
  • esophageal apical cells: 113 nCPM

Immune cell

  • NK-cell: 3.8 nTPM
  • T-reg: 1.6 nTPM
  • memory CD8 T-cell: 1.5 nTPM
  • basophil: 1.4 nTPM
  • plasmacytoid DC: 1.3 nTPM
  • naive CD8 T-cell: 1.2 nTPM

Brain region

  • white matter: 47 nTPM
  • pons: 36 nTPM
  • cerebral cortex: 34 nTPM
  • medulla oblongata: 32 nTPM
  • basal ganglia: 30 nTPM
  • spinal cord: 28 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about PLA2G6.

Disease | AllUniProt

Conditions PLA2G6 is implicated in, by any mechanism.

  • Neurodegeneration with brain iron accumulation 2B (NBIA2B) MIM:610217
  • Neurodegeneration with brain iron accumulation 2A (NBIA2A) MIM:256600
  • Parkinson disease 14 (PARK14) MIM:612953

Disease | GeneticClinVar

180 pathogenic / likely-pathogenic of 1,213 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.86
gnomAD pLI
0
gnomAD missense Z
1.21
DepMap mean gene effect
-0.11
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PLA2G6 as an antibody target. Whether an autoantibody or antibody against PLA2G6 could matter depends on whether native PLA2G6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PLA2G6 is annotated at the cell surface, where native PLA2G6 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label PLA2G6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/PLA2G6. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...